Recombinant Human Receptor-Type Tyrosine-Protein Phosphatase C (PTPRC) Protein (His)

Beta LifeScience SKU/CAT #: BLC-10762P
Greater than 90% as determined by SDS-PAGE.
Greater than 90% as determined by SDS-PAGE.

Recombinant Human Receptor-Type Tyrosine-Protein Phosphatase C (PTPRC) Protein (His)

Beta LifeScience SKU/CAT #: BLC-10762P
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description Recombinant Human Receptor-Type Tyrosine-Protein Phosphatase C (PTPRC) Protein (His) is produced by our Yeast expression system. This is a extracellular protein.
Purity Greater than 90% as determined by SDS-PAGE.
Uniprotkb P08575
Target Symbol PTPRC
Synonyms B220; CD 45; CD45; CD45 antigen; CD45R; GP180; L-CA; LCA; Leukocyte common antigen; loc; Ly-5; LY5; Ly5, homolog of; Lyt-4; OTTHUMP00000033813; OTTHUMP00000033816; OTTHUMP00000033817; OTTHUMP00000038574; Protein tyrosine phosphatase receptor type c polypeptide; Protein tyrosine phosphatase, receptor type C; protein tyrosine phosphatase, receptor type, C; Protein tyrosine phosphatase, receptor type, c polypeptide; Ptprc; PTPRC_HUMAN; Receptor-type tyrosine-protein phosphatase C; T200; T200 glycoprotein; T200 leukocyte common antigen
Species Homo sapiens (Human)
Expression System Yeast
Tag N-6His
Target Protein Sequence QSPTPSPTGLTTAKMPSVPLSSDPLPTHTTAFSPASTFERENDFSETTTSLSPDNTSTQVSPDSLDNASAFNTTGVSSVQTPHLPTHADSQTPSAGTDTQTFSGSAANAKLNPTPGSNAISDVPGERSTASTFPTDPVSPLTTTLSLAHHSSAALPARTSNTTITANTSDAYLNASETTTLSPSGSAVISTTTIATTPSKPTCDEKYANITVDYLYNKETKLFTAKLNVNENVECGNNTCTNNEVHNLTECKNASVSISHNSCTAPDKTLILDVPPGVEKFQLHDCTQVEKADTTICLKWKNIETFTCDTQNITYRFQCGNMIFDNKEIKLENLEPEHEYKCDSEILYNNHKFTNASKIIKTDFGSPGEPQIIFCRSEAAHQGVITWNPPQRSFHNFTLCYIKETEKDCLNLDKNLIKYDLQNLKPYTKYVLSLHAYIIAKVQRNGSAAMCHFTTKSAPPSQVWNMTVSMTSDNSMHVKCRPPRDRNGPHERYHLEVEAGNTLVRNESHKNCDFRVKDLQYSTDYTFKAYFHNGDYPGEPFILHHSTSYNSK
Expression Range 26-577aa
Protein Length Extracellular Domain
Mol. Weight 62.8kDa
Research Area Immunology
Form Liquid or Lyophilized powder
Buffer Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Storage 1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function Protein tyrosine-protein phosphatase required for T-cell activation through the antigen receptor. Acts as a positive regulator of T-cell coactivation upon binding to DPP4. The first PTPase domain has enzymatic activity, while the second one seems to affect the substrate specificity of the first one. Upon T-cell activation, recruits and dephosphorylates SKAP1 and FYN. Dephosphorylates LYN, and thereby modulates LYN activity.; (Microbial infection) Acts as a receptor for human cytomegalovirus protein UL11 and mediates binding of UL11 to T-cells, leading to reduced induction of tyrosine phosphorylation of multiple signaling proteins upon T-cell receptor stimulation and impaired T-cell proliferation.
Subcellular Location Cell membrane; Single-pass type I membrane protein. Membrane raft.
Protein Families Protein-tyrosine phosphatase family, Receptor class 1/6 subfamily
Database References
Associated Diseases Severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-positive (T(-)B(+)NK(+) SCID); Multiple sclerosis (MS)
Tissue Specificity Isoform 1: Detected in thymocytes. Isoform 2: Detected in thymocytes. Isoform 3: Detected in thymocytes. Isoform 4: Not detected in thymocytes. Isoform 5: Detected in thymocytes. Isoform 6: Not detected in thymocytes. Isoform 7: Detected in thymocytes. Is

Gene Functions References

  1. Overall, this study reveals the heterogeneity of CD4 effector memory T cells expressing CD45RA and provides insights into T-cell responses against dengue virus and other viral pathogens. PMID: 29133794
  2. Five-year disease-free survival for patients with a high transcriptional expression of CD45 (n = 107) was 62.4% and for patients with a low expression (n = 53) it was 36.2% (P = 0.003). Patients with a high expression of CD45 had a better local recurrence-free survival and disease-specific survival. PMID: 29177949
  3. CD45 is a regulator of IL-2 synergy in the NKG2D-mediated activation of immature human NK cells PMID: 28655861
  4. TCR phosphorylation negatively correlates with TCR-CD45 separation. PMID: 29467364
  5. Our results demonstrate that the expression of CD163 and CD206 in monocytes is modulated by LPS in vitro; LPS induces CD163 expression and downregulates the spontaneously increased expression of CD206 PMID: 25914252
  6. Our results show that the kinetic strategy used in this study may be a simple and easy approach to assess by RT-FCM the reaction between NO and superoxide ion in whole blood monocytes..The no-wash, no-lyse staining protocol with CD45-KO and CD14-PB allows to differentiate clearly and to gate in the monocyte population in near-physiological conditions PMID: 25758468
  7. regulatory effect of the mannose receptor (MR) was mediated by a direct interaction with CD45 on the T cell, inhibiting its phosphatase activity, which resulted in up-regulation of CTLA-4 and the induction of T-cell tolerance. Inhibition of CD45 prevented expression of B-cell lymphoma 6 (Bcl-6), a transcriptional inhibitor that directly bound the CTLA-4 promoter and regulated its activity PMID: 27601670
  8. pUL11 induces IL-10 producing T cells as a result of pUL11 binding to the CD45 phosphatase on T cells. PMID: 28628650
  9. Expression of IL10R subunits within the leukocyte population (CD45(+) cells) was significantly higher in primary brain tumors than in metastases. PMID: 28982901
  10. As CD45 expression vs. SSc is routinely measured in the diagnostics of acute leukemias. PMID: 26415521
  11. A phosphosite within the SH2 Domain of Lck regulates its activation by CD45. A negative feedback loop that responds to signaling events tunes active Lck amounts and TCR sensitivity. PMID: 28735895
  12. C77G is not associated with ovarian cancer in the Norwegian population. However, it is possibly associated with a less aggressive cancer type. PMID: 28759630
  13. Our findings suggest that CD45 is a key regulator of BCR-signaling thresholds mediated by T-cell help PMID: 27056269
  14. we demonstrate for the first time the physiological existence of ct-CD45 in human plasma and show that it may be an extrinsic factor contributing to the maintenance of human T-cell quiescence. PMID: 27718235
  15. Our findings suggest that if w/h ratio on SSC versus CD45 plot is less than 1.6, AML may be considered, and if it is more than 1.6, ALL may be diagnosed. Using morphometric analysis of the blast cluster on SSC versus CD45, it was possible to distinguish between ALL and AML, and their subtypes. PMID: 27748273
  16. Use of the common leukocyte marker CD45 increases the sensitivity of the diagnosis of lymphocytic myocarditis. PMID: 28025077
  17. Review/Meta-analysis: Rheumatoid arthritis patients with PTPRC rs10919563 A allele show a poor response to anti-TNF therapy. PMID: 27074847
  18. Data suggest that CD41 and CD45 expression marked the onset of haemangioblastoma (HB) neovascularisation and the stepwise development of the angioformative period, and also the underlying therapeutic targets of anti-vascular treatment. PMID: 26468019
  19. PTPRC has become the most replicated genetic biomarker of response to TNF inhibitors PMID: 25896535
  20. CD45RO in tumor-infiltrating lymphocytes was found to be a positive prognostic factor in squamous non-small cell lung cancer. PMID: 26678911
  21. CD45RO+ memory T-cells produce IL-17 in patients with atherosclerosis. PMID: 26667768
  22. Data show the structural basis for, and the potent signaling effects of, local CD45 antigen and kinase segregation. PMID: 26998761
  23. a CD45+/CD19 - cell population in bone marrow aspirates correlated with the clinical outcome of patients with mantle cell lymphoma. PMID: 25739938
  24. High CD45 expression is associated with multiple myeloma. PMID: 26994849
  25. C77G T(reg) showed diminished upregulation of activation markers, lower phosphorylation of p56(lck)(Y505) and a reduced proliferative potential when stimulated with anti-TcR or anti-TcR plus CD28 mAb suggesting decreased responsiveness to activating stimuli. Data suggest that the changes in CD45 isoform combination resulting from the C77G mutation alter the responsiveness PMID: 26355564
  26. Findings indicate that CD45 antigen(+) and c-Kit protein(+) hematopoietic cells were more abundant in muscle than in bone marrow between embryonic 14.5 and 17.5 days. PMID: 26389592
  27. CD4+CD45RO+CD25-/lowCD127+: CD4+CD45RO+CD25hiCD127-/low ratio in peripheral blood indicates heart transplant recipients at risk for cardiac allograft vasculopathy. PMID: 25539460
  28. CD45+ cells were abundant in the stroma of physiologically immature placental villi and decreased as pregnancy progressed. PMID: 25043745
  29. This study demonstrated that the copy number variations of PTPRC relate to opioid dependence. PMID: 25345593
  30. This study did not replicate the association between PTPRC and the response to anti-TNF treatment in our Southern European population. We found that TRAF1/C5 risk RA variants potentially influence anti-TNF treatment response. PMID: 25834819
  31. long noncoding RNA encoded by the natural antisense gene of CD45 contributes to the expressional regulation of the CD45RO splicing variant via recruitment of DNA methyltransferase and histone modification modulators specific to the sense gene CD45 PMID: 25381328
  32. In T-cells, cholesterol-dependent domains function in the regulation of the Src family kinase Lck (p56lck) by sequestering Lck from its activator CD45. (Review) PMID: 25658353
  33. Patients with the presence of CD8- and CD45RO-positive T cells in bone marrow demonstrated better survival of gastric cancer patients than those with the absence of these cells in bone marrow. PMID: 25804232
  34. Low expression of CD39(+) /CD45RA(+) on regulatory T cells (Treg ) cells in type 1 diabetic children in contrast to high expression of CD101(+) /CD129(+) on Treg cells in children with coeliac disease. PMID: 25421756
  35. Late-outgrowth CD45 negative endothelial progenitor cells express markers associated with pluripotency and can directly express an osteogenic phenotype under bone differentiation conditions. PMID: 25531767
  36. SLAMF7-triggered inhibition is mediated by a mechanism involving Src kinases, CD45, and SHIP-1 that is defective in MM cells PMID: 25312647
  37. Phosphatase CD45 both positively and negatively regulates T cell receptor phosphorylation in reconstituted membrane protein clusters, depending on LCK activity. PMID: 25128530
  38. Results show that CD45 PTP activity is inhibited by galectin-1 in anaplastic large cell lymphoma cell line H-ALCL. PMID: 24589677
  39. Expressing CD45 promoters containing these regions and tethered to green fluorescent protein (GFP) in a primary B-cell differentiation assay and a transplantation model resulted in high levels of GFP in lymphoid, myeloid, and nucleated erythroid cells PMID: 24852660
  40. The rare sub-population of CD45(-)/Lin(-)/SSEA-4(+) VSEL stem cells survived after Hespan sedimentation. PMID: 24364909
  41. Hematopoietic cell marker CD45 is expressed in hepatic progenitor cells. PMID: 24396288
  42. CD45RA-Foxp3high Tregs increase in the peripheral circulation of head and neck squamous cell carcinoma patients. PMID: 24761979
  43. the regulation of alternative splicing in CD45 by IkappaBL was independent from the kinase activity of CLK1. PMID: 23953137
  44. high CD45 surface expression is associated with a poor prognosis in BCP-ALL as well as in T-ALL. PMID: 23911702
  45. PTPRC/CD45 is down-regulated in leukemogenic tyrosine kinase expressing cells. PMID: 23997015
  46. [review] Circulating CD34+/KDR+/CD45dim endothelial progenitor cells have great potential as biomarkers of vasculogenesis and endothelial repair wjen research protocols of in vitro culture and flow cytometry are included. PMID: 23171577
  47. Heterogeneity within the Lin(-)CD45(-) cell fraction is the likely explanation for differences in the hUCB cell populations. PMID: 23840798
  48. Galectin-3-induced apoptosis of Jurkat cells is regulated by both O-glycans and N-glycans on CD45. PMID: 24211831
  49. spatial regulation of Lck by CD45 and GM1 ganglioside determines the outcome of apoptotic response to Gal-1 and this local regulation may occur only upon intimate effector (Gal-1 expressing) cell-T-cell attachment. PMID: 24231767
  50. A glycosylation-dependent CD45RB epitope defines previously unacknowledged CD27-(IgM high) B cell subpopulations enriched in young children and after hematopoietic stem cell transplantation. PMID: 24211716

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.

Recently viewed